Trial treatment length optimization with an emphasis on disease progression studies

Journal of Clinical Pharmacology

Volumn 49, Issue 3, 2009, Pages 323-335

  Hennig, Stefanie ^a   Nyberg, Joakim ^a   Hooker, Andrew C ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Clinical trial design; Disease progression studies; Optimal design; Pharmacometrics

Indexed keywords

ARTICLE; CLINICAL RESEARCH; DISEASE COURSE; DRUG EFFECT; DRUG RESEARCH; MEDICAL LITERATURE; SIMULATION;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; RESEARCH DESIGN;

EID: 61449220937     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008329560     Document Type: Article

References (27)

1. Mould DR, Denman NG, Duffull S. Using disease progression models as a tool to detect drug effect. Clin Pharmacol Ther. 2007 ; 82: 81-86.
2. Lockwood P., Ewy W., Hermann D., Holford N. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect: an example in Alzheimer's disease. Pharm Res. 2006 ; 23: 2050-2059.
3. Mentre F., Dubruc C., Thenot JP Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J Pharmacokinet Pharmacodyn. 2001 ; 28: 299-319.
4. Hennig S., Waterhouse TH, Bell SC, et al. A D-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol. 2007 ; 63: 438-450.
5. Green B., Duffull SB Prospective evaluation of a D-optimal designed population pharmacokinetic study. J Pharmacokin Pharmacodyn. 2003 ; 30: 145-161.
6. Maloney A., Karlsson MO, Simonsson US Optimal adaptive design in clinical drug development: a simulation example. J Clin Pharmacol. 2007 ; 47: 1231-1243.
7. Foracchia M., Hooker A., Vicini P., Ruggeri A. POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed. 2004 ; 74: 29-46.
8. Chan PL, Holford NH Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol. 2001 ; 41: 625-659.
9. Mould DR Developing models for disease progression. In: Ette EI, Williams PJ, eds. Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken, NJ: John Wiley; 2007.
10. Sheiner LB Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997 ; 61: 275-291.
11. Dodds MG, Hooker AC, Vicini P. Robust population pharmacokinetic experiment design. J Pharmacokinet Pharmacodyn. 2005 ; 32: 33-64.
12. Tod M., Rocchisani JM Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics. J Pharmacokinet Biopharm. 1997 ; 25: 515-537.
13. Waterhouse TH, Redmann S., Duffull SB, Eccleston JA Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. J Pharmacokinet Pharmacodyn. 2005 ; 32: 521-545.
14. Duffull S., Waterhouse T., Eccleston J. Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2005 ; 32: 441-457.
15. Holford NHG, Mould DR, Peck C. Disease progression models. In: Atkinson AJ, ed. Principles of Clinical Pharmacology. New York, NY: Academic Press; 2001.
16. Holford NH, Peace K. The effect of tacrine and lecithin in Alzheimer's disease: a population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol. 1994 ; 47: 17-23.
17. Chan PL, Nutt JG, Holford NH Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm Res. 2007 ; 24: 791-802.
18. Holford NH, Peace KE Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA. 1992 ; 89: 11466-11470.
19. Holford N. Modelling disease progression. Presented at: Annual Meeting of the Population Approach Group in Europe ; June 14-16, 2007 ; Copenhagen, Denmark. http://www.page-meeting.org/page/page2007/ModellingDiseaseProgression. pdf.
20. Holford NH, Chan PL, Nutt JG, Kieburtz K., Shoulson I. Disease progression and pharmacodynamics in Parkinson disease: evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn. 2006 ; 33: 281-311.
21. Boeckmann AJ, Sheiner LB, Beal S. NONMEM Users Guide. San Francisco: NONMEM Project Group, University of California, San Francisco ; 1994.
22. Lindbom L., Pihlgren P., Jonsson EN PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005 ; 79: 241-257.
23. Nyberg J., Karlsson MO, Hooker A. Sequential versus simultaneous optimal experimental design on dose and sample times. Presented at: Annual Meeting of the Population Approach Group in Europe ; June 14-16, 2007 ; Copenhagen, Denmark. www.page-meeting.org/?abstract=1160.
24. Retout S., Mentre F., Bruno R. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Stat Med. 2002 ; 21: 2623-2639.
25. Duffull SB, Mentre F., Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm Res. 2001 ; 18: 83-89.
26. Zamuner S., Gomeni R. Optimal design to estimate the time varying receptor occupancy relationship in a PET experiment. Presented at: Annual Meeting of the Population Approach Group in Europe ; June 14-16, 2007 ; Copenhagen, Denmark. www.page-meeting.org/?abstract=1099.
27. Holford NHG, Sheiner LB Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981 ; 6: 429-453.